Int J Med Sci 2019; 16(3):424-442. doi:10.7150/ijms.30154 This issue Cite

Review

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas

Qing Zhang1✉, Shaobin Wang2, Junhui Chen1, Zhendong Yu3✉

1. Department of Minimally Invasive Intervention, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China.
2. Health Management Center of Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China.
3. China Central Laboratory of Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China.

Citation:
Zhang Q, Wang S, Chen J, Yu Z. Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas. Int J Med Sci 2019; 16(3):424-442. doi:10.7150/ijms.30154. https://www.medsci.org/v16p0424.htm
Other styles

File import instruction

Abstract

T-cell lymphomas are a heterogeneous group of cancers with different pathogenesis and poor prognosis. Histone deacetylases (HDACs) are epigenetic modifiers that modulate many key biological processes. In recent years, HDACs have been fully investigated for their roles and potential as drug targets in T-cell lymphomas. In this review, we have deciphered the modes of action of HDACs, HDAC inhibitors as single agents, and HDACs guided combination therapies in T-cell lymphomas. The overview of HDACs on the stage of T-cell lymphomas, and HDACs guided therapies both as single agents and combination regimens endow great opportunities for the cure of T-cell lymphomas.

Keywords: Histone deacetylases (HDACs), T-cell lymphomas, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, combination therapy


Citation styles

APA
Zhang, Q., Wang, S., Chen, J., Yu, Z. (2019). Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas. International Journal of Medical Sciences, 16(3), 424-442. https://doi.org/10.7150/ijms.30154.

ACS
Zhang, Q.; Wang, S.; Chen, J.; Yu, Z. Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas. Int. J. Med. Sci. 2019, 16 (3), 424-442. DOI: 10.7150/ijms.30154.

NLM
Zhang Q, Wang S, Chen J, Yu Z. Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas. Int J Med Sci 2019; 16(3):424-442. doi:10.7150/ijms.30154. https://www.medsci.org/v16p0424.htm

CSE
Zhang Q, Wang S, Chen J, Yu Z. 2019. Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas. Int J Med Sci. 16(3):424-442.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image